NCT06651970 2026-02-23Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureAstraZenecaPhase 4 Recruiting60 enrolled
NCT03229200 2025-10-30Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Pharmacyclics Switzerland GmbHPhase 4 Active not recruiting297 enrolled